Clinical-stage cancer biotech Treeline sees path to public markets via reverse merger
Treeline Biosciences, an under-the-radar cancer company that has raised more than $1 billion since its 2021 founding, is looking to step into the spotlight of t...
Treeline Biosciences, an under-the-radar cancer company that has raised more than $1 billion since its 2021 founding, is looking to step into the spotlight of the public market. Treeline has announced plans to merge with omics outfit Standard BioTools and secure a listing on the Nasdaq.